World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
134
Citations
94983
World Ranking
2101
National Ranking
1187

Everett E. Vokes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Everett E. Vokes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,048 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Everett E. Vokes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Everett E. Vokes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Everett E. Vokes is affiliated with the University of Chicago in the United States and has contributed extensively to the field of Medicine, particularly focusing on Oncology, Pulmonary and Respiratory Medicine, and Otorhinolaryngology. Their research portfolio includes 337 publications in Medicine, with 120 in Oncology, 98 in Pulmonary and Respiratory Medicine, 44 in Otorhinolaryngology, 27 in Surgery, and 24 in Molecular Biology.

The main topics of their work cover a range of cancer-related subjects, including:

  • Lung Cancer Treatments and Mutations
  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Radiomics and Machine Learning in Medical Imaging

Frequent publication venues include:

  • Journal of Clinical Oncology (28 publications)
  • International Journal of Radiation Oncology*Biology*Physics (19 publications)
  • Journal of Thoracic Oncology (16 publications)
  • UNC Libraries (10 publications)
  • Clinical Cancer Research (7 publications)

Among recent significant papers associated with their research interests are:

  • "Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer" (2023), New England Journal of Medicine
  • "Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer" (2021), Journal of Clinical Oncology
  • "Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)" (2021), Journal of Clinical Oncology
  • "Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives" (2020), The Oncologist
  • "A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study" (2021), Journal of Thoracic Oncology

Their research collaborations include frequent coauthors such as:

  • Aditya Juloori (47 joint publications)
  • Ari J. Rosenberg (45 joint publications)
  • Alexander T. Pearson (45 joint publications)
  • Nishant Agrawal (43 joint publications)
  • Elizabeth A. Blair (37 joint publications)

Everett E. Vokes has been recognized as a Member of the Association of American Physicians.

Best Publications

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Head and neck cancer.

    Everett E. Vokes;Ralph R. Weichselbaum;Scott M. Lippman;Waun Ki Hong

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

    Gary M. Strauss;James E. Herndon;Michael A. Maddaus;David W. Johnstone

  • Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Denis Soulieres;Neil N. Senzer;Everett E. Vokes;Manuel Hidalgo

  • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

    Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Ezra E. W. Cohen;Fred Rosen;Walter M. Stadler;Wendy Recant

  • The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity

    Marcy A. List;Linda L. D'Antonio;David F. Cella;Amy Siston

  • Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

    Ezra E.W. Cohen;Lee S. Rosen;Everett E. Vokes;Merrill S. Kies

  • Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea

    Al B. Benson;Jaffer A. Ajani;Robert B. Catalano;Constance Engelking

  • Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

    Tanguy Y Seiwert;Zhixiang Zuo;Michaela K Keck;Arun Khattri

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • Predictors of Competing Mortality in Advanced Head and Neck Cancer

    Loren K. Mell;James J. Dignam;Joseph K. Salama;Ezra E.W. Cohen

  • Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

    Elora Gupta;Timothy M. Lestingi;Rosemarie Mick;Jacqueline Ramirez

  • Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

    Everett E. Vokes;James E. Herndon;Michael J. Kelley;M. Giulia Cicchetti

Frequent Co-Authors

Ralph R. Weichselbaum
Ralph R. Weichselbaum University of Chicago
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego
Ravi Salgia
Ravi Salgia City Of Hope National Medical Center
Theodore Karrison
Theodore Karrison University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago
Harvey M. Golomb
Harvey M. Golomb University of Chicago
Merrill S. Kies
Merrill S. Kies The University of Texas MD Anderson Cancer Center
David R. Gandara
David R. Gandara University of California, Davis
Hedy L. Kindler
Hedy L. Kindler University of Chicago
Mark K. Ferguson
Mark K. Ferguson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors to many related academic options. For those starting as registered nurses, adn to np programs online offer an efficient way to become a nurse practitioner, opening up advanced practice opportunities.

If you are interested in health outside of clinical care, a nutrition bachelor degree online can lead to roles in dietetics, wellness coaching, or health education. These paths are ideal for those passionate about preventive medicine and healthy living.

For those drawn to the administrative side of healthcare, consider pursuing cahme accredited online mha programs. This is a strong pathway to leadership in hospitals and health organizations.

Current nurses seeking career advancement may also find rn to bsn online no clinicals programs appealing, especially for working professionals needing flexible schedules.

Whether your interests are clinical, administrative, or focused on community health, there are diverse online degrees to fit your goals and busy lifestyle.

Best Scientists Citing Everett E. Vokes

Trending Scientists

Recently Published Articles